As is my usual practice, many of my ideas for blogs originate with my experiences with patients and families. Using analogies in clinical practice in order to make concepts more understandable is an excellent means to reach an “aha” moment. Oftentimes, we, as clinicians, provide very comprehensive explanations as to why certain... Read more
AFREZZA® has been approved by the FDA (Food and Drug Administration) for use in adults. What is AFREZZA?
AFREZZA is an “ultra rapid- acting mealtime insulin” that has been developed for adults with type 1 and 2 diabetes to improve glycemic control. The system includes an inhaler device that consists of AFREZZA inhalation powder... Read more
I have received a number of excited notifications from patients this past week in regard to the bionic pancreas. As such, I did my due diligence to research this new device and noted the recent scholarly paper published by Russell, El-Khatib, Sinha, Magyar, MecKeon, Goergen, Balliro, Hilliard, Nathan, and Damiano in The New England Journal... Read more
Diabetic Ketoacidosis (DKA) is a life–threatening consequence of diabetes. DKA occurs when there is a lack of insulin in the body causing hyperglycemia. As a result of the inability of glucose to enter the cells, the body must find other means to obtain energy. As such, fat breakdown occurs resulting in the accumulation of fatty acids. The... Read more
The topic of blood glucose monitoring and accuracy has been one of major concern with the continuing development of new blood glucose monitors. Indeed, I am often questioned why upon paired testing, one meter reading may be quite different from another. Generally, glucose meters are utilized to base insulin dosing as well as to monitor glucose... Read more